UK Markets closed

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.2500+0.1600 (+3.91%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.0900
Open3.9400
Bid4.2200 x 800
Ask4.3100 x 2200
Day's range3.9400 - 4.2900
52-week range2.2300 - 6.3800
Volume184,334
Avg. volume3,020,290
Market cap187.792M
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-1.2570
Earnings date23 Mar 2022 - 28 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.56
  • Globe Newswire

    InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor

    Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR. “Inhibition of the C5a/C5aR axis provides strong anti-inflammatory effects in a vari

  • Globe Newswire

    InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events

    Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at sev

  • Globe Newswire

    InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

    Phase III study to include a new primary endpoint, the modified HiSCRNew primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rdPhase III program to focus on HS patients with active draining tunnels and will start enrolling patients in Q2 JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today annou